CD274 and neoplasm: ORR with nivolumab vs. with chemo: in PD-L1+ patients (surface expression, cutoff: ≥5% tumor cells, Dako; prevalence: 49%), 43.6 vs. 9.1%; in PD-L1− patients, 20.3 vs. 13.0%